Merck KGaA to Exit Orthopedics Joint Venture to Focus on Core Businesses

18-Dec-2003 - Merck KGaA announced that it will sell its 50 percent stake in the European orthopedics joint venture BioMer C.V. for USD 300 million to its partner, Biomet Inc. of Warsaw, Indiana. Sale of the stake in the joint venture is expected to be completed in the first quarter of next year and will ...

Graffinity Pharmaceuticals Announces Further Expansion Of Medicinal Chemistry Department

01-Dec-2003 - Graffinity Pharmaceuticals AG announced that Paul J. Edwards, Ph.D. has been appointed as Associate Director of Medicinal Chemistry, effective immediately. Dr. Edwards, 35, will report to Dr. Achim Feurer, Director of Medicinal Chemistry, who in turn reports to Dr. Victor G. Matassa, Vice ...

SGI Supports Merck Research Efforts

25-Nov-2003 - The Department of Bioinformatics at Merck & Co., Inc. has turned to SGI to support ongoing informatics efforts at its Merck Research Laboratories (MRL). The global, research-driven pharmaceutical company has installed two SGI(R) Origin(R) 3000 family of servers for complete integration of ...

Merck and Toyo Aluminium Produce New Hiding Effect Pigments

20-Oct-2003 - Merck KGaA will launch innovative hiding effect pigments in a joint development with Toyo Aluminium K.K. (Osaka, Japan). The first effect pigment from this cooperation will be reddish-orange in color and will be achieved with aluminum flakes coated by ferric oxide. The product will mainly be ...

Merck KGaA's Liquid Crystal Research Team Nominated for German Future Prize

24-Sep-2003 - A team of three researchers from the Darmstadt-based pharmaceutical and chemical company Merck KGaA was nominated today in Berlin for the German Future Prize 2003. With this award the Federal Republic of Germany pays tribute to excellent technical, engineering or natural science innovations. The ...

Pharmacopeia Announces New Research Collaboration With Schering-Plough

Multiyear Agreement Extends Pharmacopeia's Largest Collaboration to Identify and Optimize New Drug Candidates

05-Sep-2003 - Pharmacopeia, Inc. announced a new drug discovery collaboration with Schering-Plough Corporation, continuing Pharmacopeia's research relationship with Schering-Plough for a minimum of three additional years. Pharmacopeia and Schering-Plough began their relationship in 1994, initially focusing ...

Merck Electronic Chemicals Signed Agreement with Moses Lake Industries, USA

22-Aug-2003 - Merck Electronic Chemicals Holding GmbH of Germany recently signed a cooperation agreement with Moses Lake Industries (MLI) of Moses Lake, Washington, USA. Both companies agree to actively market the products of the partner in their respective territories. Merck Electronic Chemicals Holding ...

Merck Acquires Direct Marketer of Vitamins, Minerals and Supplements

21-Aug-2003 - Merck KGaA announced that Merck CHC Holding, its wholly owned Consumer Health Care business, has acquired Peter Black Direct Marketing Ltd., a U.K.-based direct marketer of vitamins, minerals and supplements, in order to expand and reinforce Merck's market share in Great Britain. Peter Black ...

Merck KGaA Acquires U.S. Proteomics Company ProteoPlex

12-Aug-2003 - Merck KGaA announced today that EMD Biosciences, Inc., its United States life sciences subsidiary located in San Diego, CA, has acquired ProteoPlex, Inc. of St. Louis, MO, privately owned research and development company specializing in functional genomics and proteomics. ProteoPlex will be a ...

ICN Pharmaceuticals Resolves Arbitration With Schering-Plough on Indigent Royalty Payments

04-Aug-2003 - ICN Pharmaceuticals, Inc. announced that it received a decision in its arbitration case between ICN and its 80-percent owned subsidiary, Ribapharm Inc. and Schering-Plough Corporation. The arbitration dispute was related to royalties on ribavirin sales that were part of Schering's indigent care ...